Detalhe da pesquisa
1.
Semaglutide as a potential treatment for obesity in Smith-Kingsmore syndrome (SKS) patients: A mosaic mutation case report.
Obes Res Clin Pract
; 18(2): 159-162, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38582735
2.
Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery.
Obesity (Silver Spring)
; 32(1): 50-58, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37927153
3.
Factors associated with meropenem pharmacokinetic/pharmacodynamic target attainment in septic critically ill patients treated with extended intermittent infusion or continuous infusion.
Int J Antimicrob Agents
; 62(2): 106868, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37244425